Taranabant

Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 inverse agonist being investigated as a potential treatment for obesity due to its anorectic effects. It was discovered by Merck & Co.

As of March 2008, it is currently undergoing Phase III clinical studies.